Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai Prasad, Siddharth Reddy, Vamshi Sarangi, Brunda Ganneru, Gajanan Sapkal, Pragya D. Yadav, Priya Abraham, Samiran Panda, Nivedita Gupta, Prabhakar Reddy, Savita Verma, Sanjay Kumar Rai, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Venkat Rao, Randeep Guleria, Krishna M. Ella, Balram Bhargava
Topics & Concepts
ImmunogenicityDouble blindSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyMedicineCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakImmunologyAntibodyInternal medicinePlaceboOutbreakAlternative medicinePathologyDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesImmunotherapy and Immune Responses